Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven treatment selection versus standard randomization in rheumatoid arthritis
ISRCTN44988547Phase 4Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Feb 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of etanercept and sarilumab in rheumatoid arthritis (RA) (2 arms), sponsored by Queen Mary University of London. Started Feb 2023; status: recruiting.
02
Drugs
etanerceptsarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN44988547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44988547.